Multimodality Management of EBV-Associated Nasopharyngeal Carcinoma.

Cancers (Basel) · 2021 · PMC8657235 · PMID 34885187

Europe PMC DOI

hedged sentence

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

borderline significantp = 0.059so close (0.05 < p ≤ 0.1)

Subsequently, a small phase III trial in Tunisia/France, studying 83 patients, used the same induction regimen and found a similar improvement in 3-year PFS (HR 0.44, 95% CI 0.20–0.97; p = 0.042) but a borderline significant 3-year OS (HR 0.40, 95% CI 0.15–1.04; p = 0.059) [ 17 ].

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.